US Patent

US8828427 — Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione

Composition of Matter · Assigned to Celgene Corp · Expires 2031-06-21 · 5y remaining

Vulnerability score 15/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects formulations of the drug substance 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione.

USPTO Abstract

Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease.

Drugs covered by this patent

Patent Metadata

Patent number
US8828427
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-06-21
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.